Simplex Trading
TRDA icon

Simplex Trading’s Entrada Therapeutics TRDA Stock Holding History

Simplex Trading’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,900
Closed -$32K – 9703
2024
Q4 		$32K Buy
+1,900
New +$34.4K ﹤0.01% 6297

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Simplex Trading's TRDA Position: Q4 2024 in Review

Simplex Trading sold out of Entrada Therapeutics (TRDA) in Q4 2024, closing a stake of 1,017 shares — an estimated $18.4K sold.

Simplex Trading first reported a position in TRDA in Q3 2024 and held it in 1 quarter. The position peaked at $16K in Q3 2024. 103 funds tracked by Wall St. Rank hold TRDA as of Q4 2024.

  • Simplex Trading reported no remaining Entrada Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Simplex Trading sold 1,017 Entrada Therapeutics shares in Q4 2024, an estimated $18.4K.
  • Simplex Trading first reported a position in Entrada Therapeutics in Q3 2024 and held it in 1 quarter.
  • Simplex Trading's Entrada Therapeutics position peaked at $16K in Q3 2024.
  • 103 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q4 2024.

Based on Simplex Trading's 13F filing for Q4 2024, filed 11 Feb 2025.